Share the Video:

Interventional Psychiatry as an Indicator of the Industry: Opportunities and Warnings

Ron Beller, Richard Roston, Carlene MacMillian, David Feifel

Current interventional psychiatry treatments like TMS and S-ketamine offers critical insights into both the promises and pitfalls facing the broader psychedelic field. This session examines real-world treatments to explore what this early adoption reveals about access models, insurance, and commercialization trends. Are we learning the right lessons? What red flags are emerging?

Become a MAPS Member with a monthly donation

As a Member, you’re not just making a donation — you’re joining a community that is at the forefront of advancing research, changing policy, and evolving education around psychedelics. Join us in shaping a future where these life-changing tools are available to those who need them most.

Related Videos